Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 15/20 | 0.57 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SMO | Q99835 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5262620 | 1.00 | P2RY12 (0.57) | P2RY12SLC6A7MEN1SMO | |
| SCHEMBL5336543 | 0.85 | P2RY12 (0.57) | P2RY12MEN1SMO | |
| SCHEMBL5265427 | 0.85 | P2RY12 (0.57) | P2RY12MEN1SMO | |
| SCHEMBL5264604 | 0.83 | P2RY12 (0.60) | P2RY12SLC6A7MEN1SMO | |
| SCHEMBL5264908 | 0.83 | P2RY12 (0.60) | P2RY12SLC6A7MEN1SMO | |
| SCHEMBL5265651 | 0.83 | P2RY12 (0.65) | P2RY12MEN1 | |
| SCHEMBL5267881 | 0.83 | P2RY12 (0.50) | P2RY12SLC6A7MEN1SMO | |
| SCHEMBL5266300 | 0.83 | P2RY12 (0.50) | P2RY12SLC6A7MEN1SMO | |
| SCHEMBL5267786 | 0.82 | P2RY12 (0.64) | P2RY12SLC6A7MEN1 | |
| SCHEMBL5265493 | 0.82 | P2RY12 (0.71) | P2RY12MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844052-A1 | THIENO[2,3-D]PYRIMIDINE COMPOUNDS AS INHIBITORS OF ADP-MEDIATED PLATELETS AGGREGATION | Pharmacia & Upjohn Company LLC (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006079916-A1 | THIENO [2,3-D] PYRIMIDINE COMPOUNDS AS INHIBITORS OF ADP-MEDIATED PLATELETS AGGREGATION | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-08-03 | — | — | WO | disclosed |